Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma

This study is testing a CAR-T cell therapy — where a patient's own immune cells are re-engineered to target and kill cancer cells — for people with multiple myeloma (a blood cancer) that has come back or stopped responding to treatment. The therapy targets a protein on myeloma cells called BCMA. **You may be eligible if...** - You are 18 or older - You have multiple myeloma that has returned or is no longer responding to treatment - You have already received at least 2 prior treatment regimens, including drugs that target the proteasome and immune-modulating drugs - Your heart, kidneys, liver, and blood counts meet required levels - Your overall health is reasonably good (ECOG 0–2) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have had a stroke within the past 3 months, severe brain injury, dementia, or uncontrolled psychiatric illness - Cancer has spread to your brain or spinal cord - You have active graft-versus-host disease (from a prior bone marrow transplant) - Your blood counts or organ function are too low Talk to your doctor to see if this trial is right for you.